newsfilter
← Latest News
GlobeNewswire·

Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2026 Financial Results

  • Cogent Biosciences reported third quarter 2026 financial results with cash, cash equivalents, & marketable securities totaling $791.1 million as of September 30, 2026.
  • The company's cash balance is expected to fund operations into late 2028, covering all pending PDUFA dates for bezuclastinib.
  • PDUFA action dates are November 30, 2026 for GIST, December 30, 2026 for NonAdvSM, & June 29, 2027 for AdvSM.
  • The FDA accepted the New Drug Application for bezuclastinib in Advanced Systemic Mastocytosis (AdvSM).
  • Cogent plans to present bezuclastinib data at the 68th Annual Meeting of the American Society of Hematology (ASH) in December 2026.
  • An extension cohort of the PEAK trial investigating bezuclastinib combined with sunitinib for first-line GIST patients has been initiated.
  • Investigational New Drug applications for the JAK2 inhibitor CGT1145 & KRAS inhibitor CGT1815 are expected in Q4 2026.
  • Research & development expenses were $75.1 million for the quarter, while general & administrative expenses were $42.1 million.
  • The company reported a net loss of $111.4 million for the third quarter of 2026.
  • Cogent Biosciences will participate in investor conferences including the Guggenheim Healthcare Innovation Conference, UBS Global Biopharma Conference, Jefferies Global Healthcare Conference, & Piper Sandler Healthcare Conference.